A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

What is it about?

We examined MBX-2982 (GPR-119 agonist) to see if it could increase glucagon response to hypoglycemia in people with type 1 diabetes. While MBX-2982 increased GLP-1 hormone levels, it did not improve the body's counterregulatory responses to hypoglycemia compared to a placebo. Therefore, MBX-2982 may not be an effective treatment for improving hypoglycemia in people with type 1 diabetes.

Featured Image